PharmaACE’s Post

PharmaMonitor Feb'24 Pharmarack presents “PharmaMonitor”, a monthly webinar aimed towards topics of discussion that provide new perspectives on Healthcare dynamics in India In this curated webinar discussion, you'll find a wealth of knowledge equipped with Pharma Industry perspectives that will equip you with the intelligence needed to make informed decisions in your business calls. Stay ahead of the curve with our insights. Mark your calendars 📆 for the next edition of Pharma Monitor. Don't miss out! #PharmaMonitor #MarketTrends #PharmaceuticalIndustry #Pharmarack #ipm #pharmaceuticalindustry #analytics #pharmamarketing #pharma

Over the last three years, the #biopharma world has experienced a surge, with a sixfold increase in approved #ConnectedHealth products, now comprising 19% of the market. - The number of organizations developing or testing such products has skyrocketed from 13% to 35%. - Motivations are high, driven by the desire to enhance #PatientSupport (85%) and gain deeper clinical insights (83%). Stay abreast of all the current trends in connected health. Download our report now: https://bit.ly/3z3ofaF #LifeScience #Pharma #Medtech

💡 Ready to break free from outdated pricing strategies?   Subscription tiers are reshaping revenue models across industries. Curious how they can transform your profits? Join Vincent Blankert from Zoetis at the EPP Life Sciences Pricing Forum 2024 for an insightful session: Beyond Flea Meds: Dive Into Subscription Tiers That Offer Comprehensive Care. In this session, you’ll discover: 🔹 Cutting-edge innovations in subscription pricing 🔹 How to implement tiered models that cater to comprehensive care 🔹Proven strategies for driving both revenue growth and profitability Is your pricing strategy ready to embrace the future of subscription-based care? This session will show you how. 🔗 Download the full event brochure:  https://lnkd.in/d2KYzBZX #EPP #EPPLSPF #LSF24 #LifeSciences #Pharma #Biopharma #Medtech #PricingStrategies #Innovation #Healthcare #LifeSciences2024

Avalere's thinking about aligning HEOR planning with market dynamics in this year's budget planning was outlined in our recent article with Pharma Focus America - check it out and let me know if you want to connect!

😊 Will you be attending the 2024 Pharma CI Conference next week? Stop by and say hello! 📅 My colleague Michael Kavouksorian and I will be presenting next Thursday, 9/26! ⚡ Join us for a walkthrough of the most significant industry disruptors and explore ways CI/MI practitioners can better predict, adjust, and enhance strategies to stay competitive. We are looking forward to seeing you!! #Pharma #MeetingsAndEvents #PharmaCIUSA #PharmaCI #LifeSciences #Healthcare #CI #MI #CompetitiveIntelligence #MarketIntelligence #Insights #Strategy #StrategicDecisionMaking Fletcher #FletcherCSI #CompetitiveStrategicInsights

Market Access in Life Sciences: Real World Evidence Takes Center Stage in 2023 Real World Evidence (RWE) was the top priority in the market access landscape for the life sciences sector in 2023, followed by Artificial Engagement and Pricing. Health Technology Assessment (HTA) and Value Assessment were also considered important. Other areas of interest included Health Data Management, Patient Engagement, and Public Health. The 'Other' category highlighted emerging trends and showcased the adaptability of the market access landscape. Overall, the industry is evolving to meet the challenges of the healthcare environment. For more details please click the link! https://lnkd.in/dgbfEUmY #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical

We were at #BioTechX 2024! Introduced a White Paper about information flows in and around pharma. Gave a talk about integrating into an information ecosystem. Connected with great people and exchanged ideas. Thanks to Andrei Dmitrenko and Moritz Haag for Introducing Information Permeability! #pharma #precisionmedicine #digitaltransformation #healthcare #doneai

As we enter the budgeting season, it's crucial for 𝐇𝐄𝐎𝐑 𝐩𝐫𝐨𝐟𝐞𝐬𝐬𝐢𝐨𝐧𝐚𝐥𝐬 to rethink their evidence strategies. With the evolving healthcare landscape, organizations must adapt their value propositions to align with market dynamics. Our latest article, featuring insights from Nicole Betor, Nancy El Hoyek, Laura T. Housman, MPH, MBA, DrPH(c)-Avalere Health, 𝐉𝐨𝐬𝐢𝐞 𝐋𝐥𝐨𝐲𝐝, and Taylor Schwartz Avalere, emphasizes the importance of a phase-appropriate approach to evidence generation. The role of 𝐂𝐨𝐧𝐭𝐫𝐚𝐜𝐭 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐌𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠 𝐎𝐫𝐠𝐚𝐧𝐢𝐳𝐚𝐭𝐢𝐨𝐧𝐬 (𝐂𝐃𝐌𝐎𝐬) is pivotal in this fast-paced environment. By enhancing product development speed without compromising quality, 𝐂𝐃𝐌𝐎𝐬 enable biotech firms to navigate regulatory challenges effectively. This strategic flexibility is essential for building a robust value-based commercialization strategy. 𝐉𝐨𝐢𝐧 𝐮𝐬 𝐢𝐧 𝐞𝐱𝐩𝐥𝐨𝐫𝐢𝐧𝐠 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐯𝐞 𝐚𝐩𝐩𝐫𝐨𝐚𝐜𝐡𝐞𝐬 𝐭𝐨 𝐇𝐄𝐎𝐑 𝐛𝐮𝐝𝐠𝐞𝐭 𝐩𝐥𝐚𝐧𝐧𝐢𝐧𝐠 𝐚𝐧𝐝 𝐡𝐨𝐰 𝐢𝐧𝐭𝐞𝐠𝐫𝐚𝐭𝐢𝐧𝐠 𝐫𝐞𝐚𝐥-𝐰𝐨𝐫𝐥𝐝 𝐞𝐯𝐢𝐝𝐞𝐧𝐜𝐞 𝐜𝐚𝐧 𝐝𝐫𝐢𝐯𝐞 𝐛𝐞𝐭𝐭𝐞𝐫 𝐨𝐮𝐭𝐜𝐨𝐦𝐞𝐬. https://lnkd.in/gcVzJtiH 🔗 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐭𝐡𝐞 𝐞-𝐛𝐨𝐨𝐤 𝐧𝐨𝐰: https://lnkd.in/gdXUhnQ4 𝐕𝐢𝐬𝐢𝐭 𝐏𝐡𝐚𝐫𝐦𝐚 𝐅𝐨𝐜𝐮𝐬 𝐀𝐦𝐞𝐫𝐢𝐜𝐚: https://lnkd.in/duKnzVCp #HEOR #CDMO #budgetplanning #valuebasedcare #biotech #evidencestrategy #healtheconomics #outcomesresearch #innovation #realworldevidence #patientcentricity #marketaccess #pharma #healthcarestrategy #pharmafocusamerica #pharmafocus #pharmamagazine #pharmaarticles #pharmacovigilance #pharmaceuticals

Powered by #HealthTechAlpha, this #report offers unmatched insights into drug development efficiency, strategic collaborations and the ventures driving #DigitalHealth forward. Access the executive summary from our partners at Galen Growth | Insights You Can Trust today: https://ow.ly/UgKo50QnqeT